16 September 2021 - Surrogate outcomes provide no guarantee of clinical benefit, and Dalia Dawoud and colleagues argue they should be used only as a last resort in drug trials
In June 2021, the US FDA granted accelerated approval to aducanumab for treating Alzheimer’s disease based on the drug’s amyloid reducing effects.